SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001140361-24-002903
Filing Date
2024-01-19
Accepted
2024-01-19 16:05:30
Documents
13
Period of Report
2023-12-11
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A ef20019132_8ka.htm   iXBRL 8-K/A 35054
2 EXHIBIT 10.1 ef20019132_ex10-1.htm EX-10.1 103216
  Complete submission text file 0001140361-24-002903.txt   303907

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20231211.xsd EX-101.SCH 3908
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20231211_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20231211_pre.xml EX-101.PRE 16073
7 EXTRACTED XBRL INSTANCE DOCUMENT ef20019132_8ka_htm.xml XML 4207
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-51173 | Film No.: 24545596
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)